Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2017, Article ID 4276435, 4 pages
https://doi.org/10.1155/2017/4276435
Case Report

Squamous Cell Carcinoma of the Thyroid as a Result of Anaplastic Transformation from BRAF-Positive Papillary Thyroid Cancer

1Department of Hematology Oncology, SUNY Upstate Medical University, Syracuse, NY 13205, USA
2Department of Medicine, SUNY Upstate Medical University, Syracuse, NY 13205, USA
3Department of Pathology, SUNY Upstate Medical University, Syracuse, NY 13205, USA

Correspondence should be addressed to Alina Basnet; moc.liamtoh@anilatensab

Received 29 May 2017; Revised 17 August 2017; Accepted 14 September 2017; Published 12 October 2017

Academic Editor: Jose I. Mayordomo

Copyright © 2017 Alina Basnet et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Papillary thyroid carcinoma (PTC) is the most common malignant neoplasm of the thyroid. Majority of the PTC carries an excellent prognosis. However, patients with tall cell variant (TCV) of papillary thyroid carcinoma have a worse prognosis than those with the classic variant. On the other hand, squamous cell carcinoma of the thyroid (SCT) is an unusual neoplasm thought to arise as a primary tumor or as a component of an anaplastic or undifferentiated carcinoma. We report a patient with TCV of PTC presenting years later with squamous transformation. In addition, the patient was found to have BRAF mutation. Such dedifferentiation is considered to be a rare phenomenon and has been reported only in the form of case reports in the literature. The relationship between BRAFV600E mutation and squamous cell transformation of papillary thyroid cancer is unknown at this time. Meticulous pathology is needed to identify such variants. Our patient responded to treatment with concurrent chemotherapy with carboplatin and paclitaxel along with radiation.